[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525446":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":11,"studyPopulation":11,"armGroups":42,"interventions":61,"overallOfficials":95,"centralContacts":99,"locations":107,"responsibleParty":358,"collaborators":11,"id":360,"slug":11,"hasResults":361,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":11,"eligibilityCriteria":365,"healthyVolunteers":361,"sex":366,"minAge":367,"maxAge":11,"enrollmentInfo":368,"targetDuration":11,"studyType":371,"phases":372,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":110,"whyStopped":11,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":397},{"fullName":5,"class":6},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":23,"otherOutcomes":11},[9,13,15,17,19,21],{"measure":10,"description":11,"timeFrame":12},"Incidence of adverse events (AEs)",null,"Up to 2 years",{"measure":14,"description":11,"timeFrame":12},"Incidence of serious adverse events (SAEs)",{"measure":16,"description":11,"timeFrame":12},"Incidence of adverse events of special interest (AESI)",{"measure":18,"description":11,"timeFrame":12},"Incidence of AEs leading to discontinuation",{"measure":20,"description":11,"timeFrame":12},"Number of Deaths",{"measure":22,"description":11,"timeFrame":12},"Establish recommended Phase 2 dose (RP2D)",[24,26,28,30,32,34],{"measure":25,"description":11,"timeFrame":12},"Overall response rate (ORR)",{"measure":27,"description":11,"timeFrame":12},"Complete response rate (CRR)",{"measure":29,"description":11,"timeFrame":12},"Very good partial response rate (VGPRR)",{"measure":31,"description":11,"timeFrame":12},"Maximum observed concentration (Cmax) of arlocabtagene autoleucel",{"measure":33,"description":11,"timeFrame":12},"Time of maximum observed concentration (tmax) of arlocabtagene autoleucel",{"measure":35,"description":11,"timeFrame":12},"Area under the concentration-time curve from time 0 to 28 days [AUC (0-28D)] of arlocabtagene autoleucel",{"allocation":37,"interventionModel":38,"interventionModelDescription":11,"primaryPurpose":39,"observationalModel":11,"timePerspective":11,"maskingInfo":40},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":41,"maskingDescription":11,"whoMasked":11},"NONE",[43,49,53,57],{"label":44,"type":45,"description":11,"interventionNames":46},"Arm A: BMS-986393 + Alnuctamab","EXPERIMENTAL",[47,48],"Drug: BMS-986393","Drug: Alnuctamab",{"label":50,"type":45,"description":11,"interventionNames":51},"Arm B: BMS-986393 + Mezigdomide",[47,52],"Drug: Mezigdomide",{"label":54,"type":45,"description":11,"interventionNames":55},"Arm C: BMS-986393 + Iberdomide",[47,56],"Drug: Iberdomide",{"label":58,"type":45,"description":11,"interventionNames":59},"Arm D: BMS-986393 + Elranatamab",[47,60],"Drug: Elranatamab",[62,71,78,84,90],{"type":63,"name":64,"description":65,"armGroupLabels":66,"otherNames":67},"DRUG","BMS-986393","Specified dose on specified days",[44,50,54,58],[68,69,70],"CC-95266","Arlocabtagene autoleucel","arlo-cel",{"type":63,"name":72,"description":65,"armGroupLabels":73,"otherNames":74},"Alnuctamab",[44],[75,76,77],"BMS-986349","CC-93269","EM901",{"type":63,"name":79,"description":65,"armGroupLabels":80,"otherNames":81},"Mezigdomide",[50],[82,83],"BMS-986348","CC-92480",{"type":63,"name":85,"description":65,"armGroupLabels":86,"otherNames":87},"Iberdomide",[54],[88,89],"BMS-986382","CC-220",{"type":63,"name":91,"description":65,"armGroupLabels":92,"otherNames":93},"Elranatamab",[58],[94],"Elrexfio",[96],{"name":97,"affiliation":97,"role":98},"Bristol-Myers Squibb","STUDY_DIRECTOR",[100,105],{"name":101,"role":102,"phone":103,"phoneExt":11,"email":104},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":106,"role":102,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[108,126,140,154,168,182,196,205,218,232,246,260,272,279,289,300,314,328,344],{"facility":109,"status":110,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":121,"contacts":122},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35294-3300","United States","US",{"type":117,"coordinates":118},"Point",[119,120],-86.80249,33.52066,{"lat":120,"lon":119},[123],{"name":124,"role":102,"phone":125,"phoneExt":11,"email":11},"Susan Bal, Site 0008","205-934-1908",{"facility":127,"status":110,"city":128,"state":129,"zip":130,"country":114,"countryCode":115,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Mayo Clinic in Arizona - Phoenix","Phoenix","Arizona","85054",{"type":117,"coordinates":132},[133,134],-112.07404,33.44838,{"lat":134,"lon":133},[137],{"name":138,"role":102,"phone":139,"phoneExt":11,"email":11},"Julia Wiedmeier-Nutor, Site 0002","855-776-0015",{"facility":141,"status":110,"city":142,"state":143,"zip":144,"country":114,"countryCode":115,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"City of Hope Comprehensive Cancer Center","Duarte","California","91010",{"type":117,"coordinates":146},[147,148],-117.97729,34.13945,{"lat":148,"lon":147},[151],{"name":152,"role":102,"phone":153,"phoneExt":11,"email":11},"Myo Htut, Site 0028","626-256-4673",{"facility":155,"status":110,"city":156,"state":157,"zip":158,"country":114,"countryCode":115,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"Mayo Clinic in Florida","Jacksonville","Florida","32224",{"type":117,"coordinates":160},[161,162],-81.65565,30.33218,{"lat":162,"lon":161},[165],{"name":166,"role":102,"phone":167,"phoneExt":11,"email":11},"Vivek Roy, Site 0005","000-000-0000",{"facility":169,"status":110,"city":170,"state":171,"zip":172,"country":114,"countryCode":115,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Northside Hospital","Atlanta","Georgia","30342",{"type":117,"coordinates":174},[175,176],-84.38798,33.749,{"lat":176,"lon":175},[179],{"name":180,"role":102,"phone":181,"phoneExt":11,"email":11},"Scott Solomon, Site 0006","404-255-1930",{"facility":183,"status":110,"city":184,"state":185,"zip":186,"country":114,"countryCode":115,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Beth Israel Deaconess Medical Center","Boston","Massachusetts","02215",{"type":117,"coordinates":188},[189,190],-71.05977,42.35843,{"lat":190,"lon":189},[193],{"name":194,"role":102,"phone":195,"phoneExt":11,"email":11},"Jacalyn Rosenblatt, Site 0027","617-667-9920",{"facility":197,"status":110,"city":184,"state":185,"zip":186,"country":114,"countryCode":115,"cosmosGeoPoint":198,"geoPoint":200,"contacts":201},"Dana-Farber Cancer Institute",{"type":117,"coordinates":199},[189,190],{"lat":190,"lon":189},[202],{"name":203,"role":102,"phone":204,"phoneExt":11,"email":11},"Omar Nadeem, Site 0011","617-632-3000",{"facility":206,"status":110,"city":207,"state":208,"zip":209,"country":114,"countryCode":115,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Mayo Clinic in Rochester, Minnesota","Rochester","Minnesota","55905",{"type":117,"coordinates":211},[212,213],-92.4699,44.02163,{"lat":213,"lon":212},[216],{"name":217,"role":102,"phone":139,"phoneExt":11,"email":11},"Taxiarchis Kourelis, Site 0001",{"facility":219,"status":110,"city":220,"state":221,"zip":222,"country":114,"countryCode":115,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"University Of Nebraska Medical Center","Omaha","Nebraska","68198",{"type":117,"coordinates":224},[225,226],-95.94043,41.25626,{"lat":226,"lon":225},[229],{"name":230,"role":102,"phone":231,"phoneExt":11,"email":11},"Christopher D'Angelo, Site 0010","402-559-8110",{"facility":233,"status":110,"city":234,"state":235,"zip":236,"country":114,"countryCode":115,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"John Theurer Cancer Center at Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":117,"coordinates":238},[239,240],-74.04347,40.88593,{"lat":240,"lon":239},[243],{"name":244,"role":102,"phone":245,"phoneExt":11,"email":11},"David Siegel, Site 0004","551-996-8704",{"facility":247,"status":110,"city":248,"state":249,"zip":250,"country":114,"countryCode":115,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"Roswell Park Cancer Institute","Buffalo","New York","14263",{"type":117,"coordinates":252},[253,254],-78.87837,42.88645,{"lat":254,"lon":253},[257],{"name":258,"role":102,"phone":259,"phoneExt":11,"email":11},"Ehsan Malek, Site 0007","216-286-4441",{"facility":261,"status":110,"city":249,"state":249,"zip":262,"country":114,"countryCode":115,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"Laura and Isaac Perlmutter Cancer Center","10016",{"type":117,"coordinates":264},[265,266],-74.00597,40.71427,{"lat":266,"lon":265},[269],{"name":270,"role":102,"phone":271,"phoneExt":11,"email":11},"Jingmei Hsu, Site 0022","646-501-4848",{"facility":273,"status":274,"city":249,"state":249,"zip":275,"country":114,"countryCode":115,"cosmosGeoPoint":276,"geoPoint":278,"contacts":11},"Local Institution - 0009","COMPLETED","10032",{"type":117,"coordinates":277},[265,266],{"lat":266,"lon":265},{"facility":280,"status":110,"city":249,"state":249,"zip":281,"country":114,"countryCode":115,"cosmosGeoPoint":282,"geoPoint":284,"contacts":285},"Memorial Sloan Kettering Cancer Center","10065",{"type":117,"coordinates":283},[265,266],{"lat":266,"lon":265},[286],{"name":287,"role":102,"phone":288,"phoneExt":11,"email":11},"Sham Mailankody, Site 0012","646-608-3712",{"facility":290,"status":291,"city":292,"state":293,"zip":294,"country":114,"countryCode":115,"cosmosGeoPoint":295,"geoPoint":299,"contacts":11},"Local Institution - 0023","WITHDRAWN","Pittsburgh","Pennsylvania","15232",{"type":117,"coordinates":296},[297,298],-79.99589,40.44062,{"lat":298,"lon":297},{"facility":301,"status":110,"city":302,"state":303,"zip":304,"country":114,"countryCode":115,"cosmosGeoPoint":305,"geoPoint":309,"contacts":310},"Tennessee Oncology","Nashville","Tennessee","37203",{"type":117,"coordinates":306},[307,308],-86.78444,36.16589,{"lat":308,"lon":307},[311],{"name":312,"role":102,"phone":313,"phoneExt":11,"email":11},"Jesus Berdeja, Site 0025","615-329-0570",{"facility":315,"status":110,"city":316,"state":317,"zip":318,"country":114,"countryCode":115,"cosmosGeoPoint":319,"geoPoint":323,"contacts":324},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":117,"coordinates":320},[321,322],-95.36327,29.76328,{"lat":322,"lon":321},[325],{"name":326,"role":102,"phone":327,"phoneExt":11,"email":11},"Krina Patel, Site 0003","713-792-6662",{"facility":329,"status":110,"city":330,"state":331,"zip":332,"country":333,"countryCode":334,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Arthur J.E. Child Comprehensive Cancer Centre","Calgary","Alberta","T2N 5G2","Canada","CA",{"type":117,"coordinates":336},[337,338],-114.08529,51.05011,{"lat":338,"lon":337},[341],{"name":342,"role":102,"phone":343,"phoneExt":11,"email":11},"Nizar Bahlis, Site 0013","4032202801",{"facility":345,"status":110,"city":346,"state":347,"zip":348,"country":333,"countryCode":334,"cosmosGeoPoint":349,"geoPoint":353,"contacts":354},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9",{"type":117,"coordinates":350},[351,352],-79.39864,43.70643,{"lat":352,"lon":351},[355],{"name":356,"role":102,"phone":357,"phoneExt":11,"email":11},"Christine Chen, Site 0024","4169464501",{"type":359,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100525446",false,"NCT06121843","A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and\u002For Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component","Inclusion Criteria:\n\n* History of relapsed and\u002For refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).\n* Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).\n* Eastern Cooperative Oncology Group performance status of 0-1.\n\nExclusion Criteria:\n\n* Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).\n* Prior treatment with GPRC5D-targeting therapies.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":369,"type":370},147,"ESTIMATED","INTERVENTIONAL",[373],"PHASE1","The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and\u002For refractory multiple myeloma (RRMM).",[376],"Multiple Myeloma",[64,378,379,380,72,79,85,68,381,382,383,384,385,386,387,70],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","First-in-human","GPRC5D","GPRC5D CAR T","Cell Therapy","CAR T cell therapy","Combination therapy","elranatamab","arlocabtagene autoleucel","2026-02-13",{"date":390,"type":391},"2026-02-18","ACTUAL",{"date":393,"type":391},"2024-02-22",{"date":395,"type":370},"2028-08-01",{"name":5,"class":6},19]